Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase I Trial of Intravenous Administration of Vesicular Stomatitis Virus Genetically Engineered to Express Thyroidal Sodium Iodide Symporter (NIS) and Human Interferon Beta (hIFNb), in Patients With Metastatic or Recurrent Endometrial Cancer

NCT03120624 is registered in ClinicalTrials.gov with Mayo Clinic as lead sponsor.

NCT NCT03120624
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03120624 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase I Trial of Intravenous Administration of Vesicular Stomatitis Virus Genetically Engineered to Express Thyroidal Sodium Iodide Symporter (NIS) and Human Interferon Beta (hIFNb), in Patients With Metastatic or Recurrent Endometrial Cancer
Lead sponsor
Mayo Clinic
Phase
Phase 1
Overall status
Active, not recruiting
Start date
September 15, 2017
Completion date
January 1, 2028
Enrollment
34 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

metastatic endometrial carcinoma, recurrent endometrial adenocarcinoma, recurrent endometrial carcinoma, recurrent endometrial clear cell adenocarcinoma, recurrent endometrial endometrioid adenocarcinoma, recurrent endometrial mixed cell adenocarcinoma, recurrent endometrial serous adenocarcinoma, recurrent endometrial undifferentiated carcinoma, recurrent uterine corpus carcinosarcoma, stage iv uterine corpus cancer ajcc v7